In the description of the phenotypes, there was no mention of specific morphological, cellular, or regional features to distinguish CTE p-tau pathology from AD, primary age-related tauopathy (PART), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or other tauopathies. This evidence concerns the gene MAPT and Classical progressive supranuclear palsy.